OTLK logo

Outlook Therapeutics, Inc.

OTLK
Healthcare|Biotechnology|US
$0.44
-0.00 (-0.61%)
DCF Value
$0.95
Cash / Share
$0.08
Next Earnings Report
Dec 18, 2026
EPS est. -$0.07 · Revenue est. $2.2M
Financing Filings (last 12 months)
9
Shelf registrations / offering prospectuses — latest Aug 14, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (1)

Dec 2027
Est. completion
P3Age-Related Macular Degeneration
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
NCT05112861n=120

Recent Press Releases

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
Oct 9, 2026 · GlobeNewsWire
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor Discussion
Oct 6, 2026 · GlobeNewsWire
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
Oct 1, 2026 · GlobeNewsWire
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
Sep 22, 2026 · Business Wire
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
Sep 11, 2026 · GlobeNewsWire
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
Sep 10, 2026 · GlobeNewsWire
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
Aug 27, 2026 · GlobeNewsWire
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
Aug 27, 2026 · GlobeNewsWire
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
Aug 14, 2026 · GlobeNewsWire
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
Aug 12, 2026 · GlobeNewsWire

SEC Filings (114)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 13, 2026SC 13GPassive 5%+ stakeDocumentIndex
Sep 30, 20268-KMaterial eventDocumentIndex
Sep 18, 20268-KMaterial eventDocumentIndex
Aug 27, 20268-KMaterial eventDocumentIndex
Aug 19, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 18, 202610-QQuarterly reportDocumentIndex
Aug 17, 2026NT 10-QDocumentIndex
Aug 14, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Aug 14, 20268-KMaterial eventDocumentIndex
Aug 14, 2026424B5Offering prospectusDocumentIndex
Aug 14, 20268-KMaterial eventDocumentIndex
Aug 12, 2026424B5Offering prospectusDocumentIndex
Aug 12, 20268-KMaterial eventDocumentIndex
Jul 24, 20268-KMaterial eventDocumentIndex
Jul 24, 20268-KMaterial eventDocumentIndex
Jul 21, 2026EFFECTDocumentIndex
Jul 21, 2026424B3Offering prospectusDocumentIndex
Jul 17, 2026S-3Shelf registrationDocumentIndex
Jul 16, 20268-KMaterial eventDocumentIndex
Jul 10, 2026DEFA14AProxy / shareholder voteDocumentIndex
Jul 8, 2026DRSDocumentIndex
Jun 26, 20268-KMaterial eventDocumentIndex
Jun 16, 20268-KMaterial eventDocumentIndex
Jun 1, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Jun 1, 2026DEFA14AProxy / shareholder voteDocumentIndex
Jun 1, 2026DEF 14AProxy / shareholder voteDocumentIndex
Jun 1, 20268-KMaterial eventDocumentIndex
May 29, 20268-KMaterial eventDocumentIndex
May 29, 2026424B5Offering prospectusDocumentIndex
May 28, 20268-KMaterial eventDocumentIndex
May 26, 20268-KMaterial eventDocumentIndex
May 22, 2026PRE 14AProxy / shareholder voteDocumentIndex
May 18, 20268-KMaterial eventDocumentIndex
May 15, 202610-QQuarterly reportDocumentIndex
May 13, 2026424B5Offering prospectusDocumentIndex
May 13, 20268-KMaterial eventDocumentIndex
May 7, 2026DDocumentIndex
Apr 24, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 23, 20268-KMaterial eventDocumentIndex
Apr 23, 2026424B5Offering prospectusDocumentIndex